NASDAQ: IOBTIo Biotech Inc Stock
$1.47+0.03 (+2.08%)
Updated Apr 23, 2024
IOBT Price
$1.47
Fair Value Price
$3.23
Market Cap
$96.84M
52 Week Low
$0.82
52 Week High
$2.64
P/E
-0.74x
P/B
0.73x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$86.08M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.13
Operating Cash Flow
-$72M
Beta
0.98
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
IOBT Overview
IO Biotech Incorporated is a biopharma company developing immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103 is in clinical trials to treat melanoma, as well as lung, bladder, and head and neck cancers. IO Biotech was incorporated in 2014 and is headquartered in Copenhagen, Denmark.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how IOBT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IOBT ($1.47) is undervalued by 54.51% relative to our estimate of its Fair Value price of $3.23 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
IOBT ($1.47) is significantly undervalued by 54.51% relative to our estimate of its Fair Value price of $3.23 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
IOBT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IOBT due diligence checks available for Premium users.
Be the first to know about important IOBT news, forecast changes, insider trades & much more!
IOBT News
Valuation
IOBT fair value
Fair Value of IOBT stock based on Discounted Cash Flow (DCF)
Price
$1.47
Fair Value
$3.23
Undervalued by
54.51%
IOBT ($1.47) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IOBT ($1.47) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IOBT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IOBT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.74x
Industry
16.46x
Market
41.92x
IOBT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.73x
Industry
5.93x
IOBT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IOBT's financial health
Profit margin
Revenue
$0.0
Net Income
-$26.2M
Profit Margin
0%
IOBT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$150.7M
Liabilities
$17.6M
Debt to equity
0.13
IOBT's short-term assets ($147.26M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IOBT's short-term assets ($147.26M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IOBT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$22.8M
Investing
-$112.0k
Financing
-$10.0k
IOBT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IOBT vs Biotech Stocks
Io Biotech Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.